Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2008
Overview: Myriad is a healthcare company focused on molecular diagnostics and therapeutic product development. The company operates three segments: Research, Molecular Diagnostics, and Drug Development. The fiscal year was marked by a strategic shift following the discontinuation of its lead Alzheimer's drug candidate, Flurizan, which triggered a significant one-time revenue recognition event.
Key Financial Metrics
| Metric | Fiscal Year 2008 | Fiscal Year 2007 |
|---|---|---|
| Total Revenue | $333.6 million | $157.1 million |
| Net Income (Loss) | $47.8 million | ($35.0 million) |
| Operating Income (Loss) | $38.1 million | ($47.7 million) |
| Cash & Equivalents | $237.7 million | $143.4 million |
| Total Cash & Investments | $420.1 million | $308.3 million |
| Accumulated Deficit | ($204.6 million) | ($252.4 million) |
| Operating Cash Flow | $103.7 million | ($25.9 million used) |
Revenue Composition (2008):
- Molecular Diagnostics: $222.9 million (67%)
- Pharmaceutical Revenue: $100.0 million (30%) - Entirely from a non-refundable upfront fee from H. Lundbeck A/S.
- Research and Other: $10.8 million (3%)
Margins: Molecular diagnostic gross profit margin improved to 85% in 2008 from 79% in 2007.
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net profit of $47.8 million in 2008, reversing a net loss of $35.0 million in 2007. This was primarily driven by the recognition of a $100 million upfront fee from Lundbeck.
- Revenue Growth: Total revenue increased 112% year-over-year. Molecular diagnostic revenue grew 53% to $222.9 million due to increased testing volume and market penetration.
- Expense Increases:
- Research and Development (R&D) expenses rose 42% to $139.7 million, driven by a $20 million sublicense fee related to the Lundbeck agreement and increased clinical trial costs.
- Selling, General, and Administrative (SG&A) expenses rose 64% to $123.5 million, attributed to sales force expansion and marketing campaigns.
- Discontinuation of Flurizan: On June 30, 2008, the company announced the discontinuation of Flurizan (tarenflurbil) for Alzheimer's disease after Phase III trials failed to achieve statistical significance. This event allowed for the immediate recognition of the $100 million Lundbeck fee as revenue.
Guidance, Outlook, and Risks
Strategic Review: Management is conducting a comprehensive review of strategic alternatives, including potentially separating the molecular diagnostic business from the pharmaceutical business into independent entities.
Drug Development Pipeline:
- Azixa: Phase 2 trials for brain tumors (vascular disruption agent/tubulin inhibitor).
- Vivecon: Phase 1 trials for AIDS (viral maturation inhibitor).
- MPC-2130: Phase 1 trials for hematologic cancers.
- MPC-3100: Late-stage preclinical for solid tumors.
- MPC-0920: Completed Phase 1 for thrombosis; seeking partnership.
Liquidity Outlook: Management believes existing capital resources ($420.1 million in cash and investments) are sufficient to fund operations for at least the next two years. The company has a shelf registration allowing for up to $43.4 million in additional securities sales.
Key Risks:
- Regulatory Approval: High risk of failure for therapeutic candidates in clinical trials.
- Reimbursement: Dependence on third-party payors for molecular diagnostic products.
- Intellectual Property: Risks related to patent infringement claims and the ability to protect proprietary technology.
- Concentration: Reliance on a single laboratory facility in Salt Lake City for all molecular diagnostic testing.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue growth excluding the one-time $100 million Lundbeck fee. Core molecular diagnostic growth is the primary recurring revenue driver.
- Flurizan Termination Costs: Confirm the extent of ancillary costs associated with terminating the Flurizan program and whether the $3.0 million estimated cancellation cost is accurate.
- Strategic Separation: Monitor the outcome of the management review regarding the potential separation of the diagnostics and pharmaceutical segments.
- Clinical Trial Progress: Track the results of Phase 2 trials for Azixa and Phase 1 trials for Vivecon, as these are the most advanced therapeutic candidates.
- Patent Litigation: Review any pending or new litigation regarding the company's core patents (e.g., BRCA1/BRCA2) which are critical to the diagnostics business.